Celltrion has filed a petition for inter partes review (IPR2017-00959) of Genentech’s U.S. Patent 8,591,897. According to the petition, the patent is directed to methods of treating a sub-type of breast cancer with a regimen that includes trastuzumab. Trastuzumab is marketed by Genentech under the trade-name Herceptin®.
This petition and other important documents from inter partes review proceedings of biologic patents are posted on our IPR tracker page.
The post Celltrion Files Petition for IPR of Genentech’s Trastuzumab Patent appeared first on Big Molecule Watch.